Human-derived bacteria that induce proliferation or accumulation of regulatory T cells

Patent metadata

Field	Value
Publication number	US-11547732-B2
Application number	US-202017071425-A
Country	US
Kind code	B2
Filing date	Oct 15, 2020
Priority date	Dec 1, 2011
Publication date	Jan 10, 2023
Grant date	Jan 10, 2023

Abstract

Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.

First claim

What is claimed is:

1. A method of treating graft versus host disease in a subject, the method comprising administering a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacteria comprising 16S rDNA sequences of at least 95% homology to SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:40, SEQ ID NO:41, or SEQ ID NO:42 to the subject in an amount sufficient to treat the graft versus host disease.

2. The method of claim 1 , wherein the graft versus host disease is graft versus host disease following bone marrow transplant.

3. The method of claim 1 , wherein the purified bacterial mixture comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 11 bacterial strains.

4. The method of claim 1 , wherein the purified bacterial mixture comprises two or more bacterial strains comprising 16S rDNA sequence of at least 95% homology to SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, or SEQ ID NO:40.

5. The method of claim 1 , wherein the bacterial strains are human-derived bacteria.

6. The method of claim 1 , wherein the bacterial strains are isolated from a chloroform-treated fecal sample or a heat-treated fecal sample.

7. The method of claim 1 , wherein at least a portion of the bacterial strains are in spore-form.

8. The method of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

9. The method of claim 1 , wherein the pharmaceutical composition is lyophilized.

10. The method of claim 1 , wherein the pharmaceutical composition comprises one or more enteric polymers.

Assignees

• Univ Tokyo
• School Corporation Azabu Veterinary Medicine Educational Inst

Inventors

• Honda Kenya
• Atarashi Koji
• Tanoue Takeshi
• Hattori Masahira
• Morita Hidetoshi

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C12N1/205

  Bacterial isolates · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K35/741

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title